Browse All

Current Filters

CLEAR FILTER x

TITLE

OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis

Author:Newsome, Scott   Krzystanek, Ewa   Selmaj, Krzysztof   Goldstick, Lawrence   Figueiredo, Catarina   Townsend, Ben   Wolf, Christian   Zecevic, Dusanka   Giacobino, Caroline   Bortolami, Oscar   Shen, Yun-An   Kletzl, Heidemarie   Clinch, Susanne   Centonze, Diego   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.006  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  School of Health Sciences in Katowice, Katowice, Poland  Centrum Neurologii, Lodz, Poland  University of Cincinnati, Cincinnati, OH  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Lycalis sprl, Brussels, Belgium  Genentech, San Fransisco, CA  Tor Vergata University, Rome, Italy  

OCARINA I, Phase Ib Study: Dose Selection of Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis

Author:Newsome, Scott   Goldstick, Lawrence   Townsend, Ben   Zecevic, Dusanka   Augustin, Aisha   Figueiredo, Catarina   Clinch, Susanne   Giacobino, Caroline   Bortolami, Oscar   Shen, Yun-An   Kletzl, Heidemarie   Bermel, Robert   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.003  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  University of Cincinnati, Cincinnati, OH  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Roche Products Ltd. , Welwyn, United Kingdom  Genentech, San Fransisco, CA  Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH